Seres Therapeutics, Inc. (MCRB) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Seres Therapeutics is a clinical-stage biopharmaceutical company focused on developing live biotherapeutics for oncology and inflammatory/immune diseases. The company sold its approved product, VOWST, to Nestlé Health Science in September 2024. As of June 30, 2026, the company had 9,941,261 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $1.1 million (Grant revenue) | $0 |
| Net Loss | $(15.3) million | $12.8 million (Net Income) |
| Loss from Operations | $(42.2) million | $(52.1) million |
| Cash and Cash Equivalents | $15.6 million | $45.8 million (Dec 31, 2025) |
| Operating Cash Flow | $(38.8) million | $13.6 million |
| Accumulated Deficit | $(987.7) million | $(972.4) million |
Material Changes vs. Prior Period
- Net Income to Loss: The company reported a net loss of $15.3 million for the six months ended June 30, 2026, compared to net income of $12.8 million in the same period in 2025. This reversal is primarily due to a significant decrease in "Gain on sale of VOWST Business" ($25.0 million in 2026 vs. $52.4 million in 2025) and the absence of Transition Services Agreement (TSA) reimbursement income.
- Impairment Charges: The company recognized a non-cash impairment loss of $5.8 million related to long-lived assets (operating lease right-of-use assets and leasehold improvements) due to a lease amendment reducing its facility footprint.
- Expense Reductions: Operating expenses decreased by $8.8 million year-over-year, driven by a 30% workforce reduction in February 2026, the conclusion of the TSA with Nestlé, and paused investment in the SER-155 Phase 2 study.
- Liquidity: Cash and cash equivalents declined from $45.8 million at year-end 2025 to $15.6 million at June 30, 2026, reflecting a net cash burn of $36.6 million.
Guidance, Outlook, and Risks
- Going Concern: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for 12 months from the filing date. The company anticipates requiring additional funding following the first quarter of 2027.
- Capital Resources: The company expects to receive a total of $25.0 million in Milestone Termination Payments from Nestlé (SPN) in two installments ($12.5 million in July 2026 and $12.5 million in October 2026). The first installment was received in July 2026.
- Strategic Actions: The company has paused investment in the SER-155 Phase 2 study in allo-HCT while seeking funding. It continues to advance SER-155 in immune checkpoint-related enterocolitis (irEC) and early-stage programs like SER-428 (supported by a CARB-X grant).
- Cost Reductions: Significant cost-cutting measures were implemented, including a 30% workforce reduction and lease amendments to reduce facility costs.
- Risks: Key risks include the inability to raise additional capital, potential delisting from Nasdaq if stock price requirements are not met, and the uncertainty of clinical trial outcomes for pipeline candidates.
Investor Verification Checklist
- Verify the receipt and timing of the remaining $12.5 million Milestone Termination Payment from Nestlé due in October 2026.
- Monitor the company's cash burn rate and progress in securing additional financing or strategic partnerships to extend the cash runway beyond Q1 2027.
- Review the status of the SER-155 Phase 2 study in allo-HCT and the criteria for resuming investment.
- Assess the impact of the lease amendments and impairment charges on future operating costs.
- Check for any updates regarding Nasdaq listing compliance, given the company's history of bid price deficiencies.